TransThera Sciences' (HKG:2617) board approved the conversion of nearly 45 million domestic shares held by 10 shareholders into Hong Kong-listed shares, a Monday Hong Kong bourse filing said.
The shares represent roughly 11.33% of the biopharmaceutical company's issued share capital.
The Hong Kong-listed share full circulation is subject to the finalization of all details, as well as the relevant regulatory approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.